Connect with us

Hi, what are you looking for?

POZ

For PLHIV, shorter weekly course of rifapentine-isoniazid associated with higher treatment completion rates

A lesson in HIV treatment: The researchers found that tuberculosis preventive therapy with short-course, weekly rifapentine and isoniazid for 3 months was associated with much higher treatment completion rates compared with standard daily isoniazid for 6 months.

Photo by James Yarema from Unsplash.com

A randomized trial found that treatment completion was higher among persons with HIV infection who were assigned a shorter course of rifapentine-isoniazid therapy to prevent tuberculosis disease compared to those taking a longer course. A second round of treatment provided no additional protection from developing tuberculosis disease in high-transmission areas.

The findings are published in Annals of Internal Medicine.

Tuberculosis preventive therapy for persons with HIV is effective, but its durability is uncertain. In the WHIP3TB trial (Weekly High Dose Isoniazid and rifapentine [P] Periodic Prophylaxis for TB trial), researchers from the Aurum Institute, Houghton, South Africa, hypothesized that, among persons with HIV receiving antiretroviral therapy, treatment completion of weekly rifapentine and isoniazid for 3 months would be superior to 6 months of daily isoniazid, and that annual weekly rifapentine and isoniazid for 3 months would be more effective than a single round.

The researchers randomly assigned 4,014 persons with HIV who were receiving antiretroviral therapy and did not have active tuberculosis to receive weekly rifapentine–isoniazid for 3 months, given either annually for 2 years or once, or daily isoniazid for 6 months. Participants were screened for tuberculosis symptoms at months 0 to 3 and 12 of each study year and at months 12 and 24. Treatment completion rates as well as the effectiveness of the different regimens were compared.

The researchers found that tuberculosis preventive therapy with short-course, weekly rifapentine and isoniazid for 3 months was associated with much higher treatment completion rates compared with standard daily isoniazid for 6 months. In settings with high tuberculosis transmission, a second round of short-course tuberculosis preventive therapy one year later did not provide additional benefit.

Advertisement
Advertisement

Like Us On Facebook

YOU MAY ALSO LIKE

NEWSMAKERS

Does the church play a role in dealing with #HIV? For the Northern Sanctuary-Metropolitan Community Church, there is a need to "reach our flock"....

From the Editor

Among others, nevirapine caused skin breakout, while efavirenz made people have lucid dreams (and was noted to impact the bone). Dolutegravir is supposed to...

POZ

From January to March 2024, the country logged 3,410 new HIV cases, according to latest data from the Department of Health’s (DOH) HIV &...

POZ

A medication used to treat diabetes and obesity – and touted on social media for weight loss – can be a powerful weapon against...

Advertisement